Astegolimab for treating chronic obstructive pulmonary disease in people aged 40 to 80 years

Astegolimab is currently in clinical development for the treatment of chronic obstructive pulmonary disease (COPD) in patients aged 40 to 80 years who are former or current smokers and have a history of frequent exacerbations. COPD is the name for a group of lung conditions that cause breathing difficulties. It is a disease that causes obstructed airflow to and from the lungs. It is typically caused by long-term exposure to irritating gasses or matter, most often from cigarette smoke. There may be periods when the symptoms suddenly get worse, known as a flare-up or exacerbation. Many patients continue to have exacerbations despite the use of current therapies to address the symptoms of COPD, and there is a lack of treatments to improve lung function or stop disease progression.